Montpellier, France, and Lexington, MA — September 3rd, 2020 — CILcare, world leading CRO specialized in the field of hearing, announced today that Dr. Marie-Pierre PASDELOU, CILcare’s co-founder and current Chief Development Officer, is taking over CILcare’s Regulatory Affairs and Quality Department as Chief Regulatory Officer. In parallel to offering CILcare’s sponsors strategic and operational regulatory support throughout all phases of drug, biological, and medical device development, Marie-Pierre will continue to head CILcare Inc. based in Lexington, MA (USA).
Dr. Pasdelou has more than 25 years of experience in the pharmaceutical industry as a drug developer and Head of a regulatory International Department in Sanofi. Before founding CILcare alongside Celia BELLINE and Sylvie PUCHEU, Marie-Pierre held key leadership roles in R&D projects involving international registration, market access strategy, and management of external partners within consortiums of academics, universities, CROs and industries. Throughout her career, she developed a keen interest in public health, especially for aging populations before devoting herself to hearing disorders.
“I’m thrilled to start working in this new role at CILcare” comments Marie-Pierre. “Helping Sponsors develop and pursue the right regulatory pathways for their preclinical programs in order to reach the IND is really exciting. It involves regulatory strategies, applications, submissions, and interactions with regulatory agencies around the globe. I’m also particularly committed to patient associations. I believe that it is essential, even for a CRO which operates business with industries, to maintain a link with the people who are waiting for effective treatment for hearing loss or tinnitus.”
“The auditory field has few established guidelines in comparison to other therapeutics areas. This is why it is crucial for drug and device developers to be guided by experts in this domain. CILcare provides years of experience and expertise, with regulatory agency interactions and a proven history of success” stated Celia Belline, Chief Executive Officer at CILcare. “Marie-Pierre brings unmatched regulatory expertise to our clients. We know this appointment is a high added value for CILcare and our Sponsors.”
With her extensive knowledge of regulatory challenges throughout the preclinical and clinical development process, Marie-Pierre is the right person to lead CILcare and the auditory CRO field into a new era. We welcome her to this new role and are excited to support her efforts to help shape the future to make hearing a priority.
CILcare, with headquarters in Montpellier, France, and offices in Paris and Boston, is a CRO specializing in otology. CILcare has state-of-the-art laboratories, research experts in otology and neuroscience, as well as a global network of partners, enabling CILcare to offer fully customizable and comprehensive R&D programs including pharmacokinetics, preclinical efficacy, and GLP ototoxicology studies. Learn more about CILcare’s expert R&D services dedicated to ear disorders.
CBSET, with headquarters in Lexington, Mass., is the preclinical research leader in critically important therapeutic fields such as interventional cardiology, renal disease and dialysis, chronic drug-resistant hypertension, women’s health, minimally invasive surgery, orthopedics, biological and synthetic tissue repair, drug delivery, bioresorbable devices, and combination medical device and drug-eluting products. Learn more about CBSET’s expert biomedical research services.